Penumbra Inc (PEN) EVP Sells $3,595,600.00 in Stock
Penumbra Inc (NYSE:PEN) EVP Robert D. Evans sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $89.89, for a total transaction of $3,595,600.00. Following the sale, the executive vice president now owns 11,704 shares of the company’s stock, valued at approximately $1,052,072.56. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Penumbra Inc (NYSE:PEN) traded down $5.95 during trading on Thursday, reaching $84.60. 1,104,347 shares of the company traded hands, compared to its average volume of 595,467. Penumbra Inc has a 12-month low of $64.85 and a 12-month high of $116.35. The firm has a market cap of $2,870.00 and a P/E ratio of 402.86.
Penumbra (NYSE:PEN) last posted its earnings results on Tuesday, November 7th. The company reported $0.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.07. Penumbra had a negative net margin of 2.19% and a negative return on equity of 1.95%. The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $79.17 million. During the same quarter last year, the firm earned ($0.04) EPS. The firm’s revenue for the quarter was up 24.9% on a year-over-year basis. analysts predict that Penumbra Inc will post -0.15 EPS for the current year.
A number of brokerages have recently issued reports on PEN. BMO Capital Markets downgraded shares of Penumbra from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $117.00 to $110.00 in a report on Tuesday, December 12th. They noted that the move was a valuation call. Canaccord Genuity raised their price target on shares of Penumbra from $100.00 to $113.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. Zacks Investment Research upgraded shares of Penumbra from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, JPMorgan Chase & Co. downgraded shares of Penumbra from an “overweight” rating to a “neutral” rating in a report on Tuesday. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $111.50.
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.